In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis

Clinical Microbiology and Infection

Volumn 16, Issue 5, 2010, Pages 470-472

  De Backer, E ^a   Dubreuil, L ^b   Brauman, M ^c   Acar, J ^d   Vaneechoutte, M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Department of Pharmaceutical Sciences   (France)

^c Laboratoires IPRAD   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Atopobium vaginae; Bacterial vaginosis; Metronidazole; Resistance; Secnidazole

Indexed keywords

METRONIDAZOLE; SECNIDAZOLE;

AGAR DILUTION; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ATOPOBIUM VAGINAE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL; VAGINITIS;

ATOPOBIUM VAGINAE; BACTERIA (MICROORGANISMS); GARDNERELLA VAGINALIS;

EID: 77952905552     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02852.x     Document Type: Note

References (14)

1. Verhelst R, Verstraelen H, Claeys G. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis. BMC Microbiol 2004, 4:16.
2. Bradshaw CS, Tabrizi SN, Fairley CK, Morton AN, Rudland E, Garland SM. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis 2006, 194:828-836.
3. Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis 2008, 47:33-43.
4. Swidsinski A, Mendling W, Loening-Baucke V. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005, 106:1013-1023.
5. Gillis JC, Wiseman LR. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 1996, 51:621-638.
6. Dubreuil L, Calvet L, Behra J. Le secnidazole: activite antibactérienne sur les anaérobies stricts. Antibiotiques 2005, 7:239-246.
7. De Backer E, Verhelst R, Verstraelen H. Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis 2006, 6:51.
8. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL, Martin DH. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 2004, 4:5.
9. Ericsson HM, Sherris JC. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand B Microbiol Immunol 1971, 217(suppl 217):S1-S90.
10. Davis B, Glover DD, Larsen B. Analysis of metronidazole penetration into vaginal fluid by reversed-phase high-performance liquid chromatography. Am J Obstet Gynecol 1984, 149:802-803.
11. Mattila J, Mannisto PT, Mantyla R, Nykanen S, Lamminsivu U. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother 1983, 23:721-725.
12. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999, 36:353-373.
13. Theron MM, Janse Van Rensburg MN, Chalkley LJ. Nitroimidazole resistance genes (nimb) in anaerobic gram-positive cocci (previously Peptostreptococcus spp.). J Antimicrob Chemother 2004, 54:240-242.
14. Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis 2008, 47:1426-1435.